Compare Amgen, Inc. (AMGN) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SYSCO Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while SYSCO Corporation trades at $84.35 (market cap $40.09B). The key difference: Amgen, Inc. is far larger — about 4.9× SYSCO Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SYY | |
|---|---|---|
Market Cap | $196.12B | $40.09B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $91.16 |
52-Week Low | $271.18 | $69.30 |
Enterprise Value | $241.41B | $53.57B |
Dividend Yield | 2.77% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SYY trades at $83.83, up 2.19% today, near the consensus price target of $83.67. The stock shows bullish technical signals with strong moving averages and support at $81. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 missed slightly. Revenue grew to $81.37B in 2025, with net income of $1.83B. The company maintains a dividend with the next payment scheduled for July 2026.
Outlook remains positive with 60% analyst buy ratings and a high target of $86. Risks include margin pressure from rising costs and competitive threats. The transformative Restaurant Depot acquisition could drive long-term growth, but investors should monitor execution and macroeconomic impacts on food distribution demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
